ESC Premium Access

A global view: the rationale for aggresive LDL lowering

Congress Session

About the speaker

Professor Steven E Nissen

Cleveland Clinic Foundation, Cleveland (United States of America)
11 presentations
0 follower

3 more presentations in this session

Cholesterol metabolism and the role of PCSK9

Speaker: Professor S. Nicholls (Melbourne, AU)


Show me the data: clinical efficacy, safety and indications of PCSK9 inhibition

Speaker: Professor J. Jukema (Leiden, NL)


Are there effects of PCSK9 inhibitors beyond cholesterol lowering?

Speaker: Professor B. Cariou (Nantes, FR)


Access the full session

PCSK9 inhibition - cholesterol reduction and beyond

Speakers: Professor S. Nissen, Professor S. Nicholls, Professor J. Jukema, Professor B. Cariou

About the event



26 August - 30 August 2017

Sessions Presentations

Related content

Open Access

LDL-c in the management of high CV risk: Changing the paradigm for prevention.

27 August 2021

ESC Premium Access

Will coronary atherosclerosis be eliminated?

27 August 2021

ESC Premium Access

REDUCE-IT PRIOR MI: Reduction in Ischemic Events, Including Cardiovascular Mortality, with Icosapent Ethyl in Patients with Prior Myocardial Infarction

27 August 2021

This platform is supported by

logo Novo Nordisk